Baseline patient characteristics of patients with a negative PET2 scan by progression status
| . | Nonprogressor, n = 206 . | Progressor, n = 64 . | 2-sided Fisher's exact P . |
|---|---|---|---|
| Age, median (range), y | 31.8 (18.1-60.6) | 32.25 (19.1-60.8) | .52* |
| Sex, n (%) | .32 | ||
| Male | 118 (78.7) | 32 (21.3) | |
| Female | 88 (73.3) | 32 (26.7) | |
| Race, n (%) | .04 | ||
| White | 176 (78.9) | 47 (21.1) | |
| Other | 30 (63.8) | 17 (36.2) | |
| Stage, n (%) | .06 | ||
| III | 116 (81.1) | 27 (18.9) | |
| IV | 90 (70.8) | 37 (29.1) | |
| B symptoms, n (%) | 123 (77.4) | 36 (22.6) | .66 |
| Bulk >10 cm, n (%) | 36 (76.6) | 11 (23.4) | 1.00 |
| IPS, n (%) | .15 | ||
| 0-2 | 119 (79.9) | 30 (20.1) | |
| 3-7 | 87 (71.9) | 34 (28.1) | |
| PET2 Deauville score, n (%) | .19 | ||
| 1-2 | 127 (79.4) | 33 (20.6) | |
| 3 | 79 (71.8) | 31 (28.2) |
| . | Nonprogressor, n = 206 . | Progressor, n = 64 . | 2-sided Fisher's exact P . |
|---|---|---|---|
| Age, median (range), y | 31.8 (18.1-60.6) | 32.25 (19.1-60.8) | .52* |
| Sex, n (%) | .32 | ||
| Male | 118 (78.7) | 32 (21.3) | |
| Female | 88 (73.3) | 32 (26.7) | |
| Race, n (%) | .04 | ||
| White | 176 (78.9) | 47 (21.1) | |
| Other | 30 (63.8) | 17 (36.2) | |
| Stage, n (%) | .06 | ||
| III | 116 (81.1) | 27 (18.9) | |
| IV | 90 (70.8) | 37 (29.1) | |
| B symptoms, n (%) | 123 (77.4) | 36 (22.6) | .66 |
| Bulk >10 cm, n (%) | 36 (76.6) | 11 (23.4) | 1.00 |
| IPS, n (%) | .15 | ||
| 0-2 | 119 (79.9) | 30 (20.1) | |
| 3-7 | 87 (71.9) | 34 (28.1) | |
| PET2 Deauville score, n (%) | .19 | ||
| 1-2 | 127 (79.4) | 33 (20.6) | |
| 3 | 79 (71.8) | 31 (28.2) |
Two-sided Wilcoxon score test.